Treatment Outcomes of Single-Dose Liposomal Amphotericin B–Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India
The American Journal of Tropical Medicine and Hygiene · 2024
DOI: 10.4269/ajtmh.23-0640 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2024. Verfasst von Niyamat Ali Siddiqui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Indian Council of Medical Research (ICMR)-Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India. Hauptthemen laut MEDLINE: Amphotericin B, Leishmaniasis, Visceral, Antiprotozoal Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
An assessment of the treatment outcomes of single-dose liposomal amphotericin B, implemented in 2010, had not been conducted until this study. This prospective cross-sectional study encompassed 527 cases, comprising 470 (89%) cases of visceral leishmaniasis (VL) and 57 (11%) cases of post–kala-azar dermal leishmaniasis (PKDL). The male proportion was higher (55% for VL), and the mean (±SD) age was 39.2 (±33.9) years. Among VL cases (426) treated with single-dose liposomal amphotericin B, 402 cases were cured at the 6-month follow-up, resulting in a cure rate of 95%, whereas fewer than 1% (0.9%) experienced unsuccessful outcomes and 4.1% faced relapse. A statistically highly significant difference in treatment outcomes (successful versus unsuccessful) was observed between males and females ( P = 0.0005). Males had higher odds of successful outcomes compared with females, with an odds ratio of 5.03 (95% CI: 1.84–13.74). Those aged ≤23 years had higher odds of successful outcomes than unsuccessful outcomes, with an odds ratio of 6.82 (95% CI: 2.29–20.33). Patients with PKDL had a mean (±SD) age of 28.5 (±10.6) years, with 63% being male. Among the 57 PKDL cases, 21 (37%) had been treated with single-dose liposomal amphotericin B, whereas others had received alternative drugs. The median duration of PKDL development for single-dose liposomal amphotericin B was significantly shorter (14.5 months), with a statistically significant difference ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Indian Council of Medical Research (ICMR)-Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), Patna, India.
- Department of Pharmacology, School of Pharmaceutical Science, Lovely Professional University, Phagwara, India.
- Department of Microbiology, School of Sciences, RK University, Rajkot, India.
Zitieren
APA
Siddiqui, N. A., Ansari, M. Z., Sinha, S. K., Pal, B., Singh, A. K., Singh, S. K., Topno, R. K., Rabi Das, V. N., & Pandey, K. (2024). Treatment Outcomes of Single-Dose Liposomal Amphotericin B–Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.23-0640
Vancouver
Siddiqui NA, Ansari MZ, Sinha SK, Pal B, Singh AK, Singh SK, et al. Treatment Outcomes of Single-Dose Liposomal Amphotericin B–Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India. The American Journal of Tropical Medicine and Hygiene. 2024. doi:10.4269/ajtmh.23-0640
BibTeX
@article{Siddiqui2024,
author = {Siddiqui, Niyamat Ali and Ansari, Mohd Zahid and Sinha, Sanjay Kumar and Pal, Biplab and Singh, Ashish Kumar and Singh, Subhankar Kumar and Topno, Roshan Kamal and Rabi Das, Vidya Nand and Pandey, Krishna},
title = {Treatment Outcomes of Single-Dose Liposomal Amphotericin B–Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2024},
doi = {10.4269/ajtmh.23-0640}
}
EUVIMED